Epeius Biotech Awarded Patents in Europe for Targeted Genetic Anti-Cancer Medicine: Company Expands Impressive Intellectual Property Estate
Corporation, a leader in tumor-targeted gene delivery systems, has received
two additional European patents for the platform targeting technologies and
molecular designs that enable precision gene delivery to primary cancers and
metastatic lesions that have spread throughout the body. With profound
demonstrations of clinical benefit and single-agent-efficacy, as well as
overall safety, Epeius Biotech continues to lead the field of clinical gene
medicine with the advent of pathotropic (or disease-seeking) targeting. These
latest EU patents follow on the heels of a major clinical patent that was
recently awarded in the
these clinical patents provide additional intellectual property protection for
the platform of highly advanced biotechnologies embodied in the company’s
leading anti-cancer agent Rexin-G(R) — the first and so far only
tumor-targeted gene delivery system that has been successfully validated in
the clinic.
Based on recent breakthroughs in tumor-targeting and nanotechnology, a new
generation of powerful biological anti-cancer agents that are exceedingly
precise and highly selective for diseased tissues is currently in clinical
development. Anti-cancer agents such as Rexin-G(R) can be delivered by simple
intravenous infusion, yet are programmed to seek-out and accumulate
selectively in primary and metastatic lesions that have spread throughout the
body, delivering a tumor-killing gene while sparing normal cells and tissues.
Representing the world’s first targeted genetic medicine proven to be both
safe and effective in the clinic, Rexin-G(R) is commercially available in
Philippines
chemotherapy — and is currently in clinical trials in the
types of cancer.
About Epeius Biotechnologies
Epeius Biotechnologies Corporation is a privately held biopharmaceutical
company dedicated to the advancement of genetic medicine with the development
and commercialization of its proprietary targeted delivery systems. To learn
more about our pipeline of proprietary biotechnologies currently available for
clinical development and/or new product development, please visit us at
http://www.epeiusbiotech.com.
For more information about Rexin-G(R), on-going clinical trials in the
and abroad, and/or Epeius pathotropic (disease-seeking) gene delivery systems,
please contact
*(LOGO 72dpi: Send2press.com/mediaboom/08-0421-Epeius_72dpi.jpg)
This release was issued on behalf of the above organization by
Send2Press(R), a unit of Neotrope(R). http://www.Send2Press.com
SOURCE Epeius Biotechnologies